Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Carmel Jo Pezaro"'
Publikováno v:
Annual Review of Medicine. 64:1-13
Suppression of gonadal androgens by medical or surgical castration remains the mainstay of treatment for patients with advanced prostate cancer. However, the response to treatment is not durable, and transition to a “castration-resistant” state i
Publikováno v:
Management of Castration Resistant Prostate Cancer ISBN: 9781493911752
Multiple survival-prolonging treatments have now been established in castration-resistant prostate cancer (CRPC) and molecular analyses have identified further potential therapeutic targets. Optimizing the clinical development of novel anticancer dru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94f1be10b1d88963106a1e402b460760
https://doi.org/10.1007/978-1-4939-1176-9_13
https://doi.org/10.1007/978-1-4939-1176-9_13
Autor:
Jose Manuel Ruiz Morales, Marcin Swierkowski, Connor Wells, Anna Paola Fraccon, Francesca La Russa, Frede Donskov, Georg A. Bjarnason, Jae-Lyun Lee, Hao-Wen Sim, Benoit Beuselinck, Lori Wood, Takeshi Yuasa, Carmel Jo Pezaro, Brian I. Rini, Cezary Szczylik, Toni K. Choueiri, Daniel Yick Chin Heng
Publikováno v:
Journal of Clinical Oncology. 34:4510-4510
Autor:
Alexa Gillman, A. Jayaram, Nuria Porta, Pasquale Rescigno, Michael Paul Kolinsky, Praful Ravi, Diletta Bianchini, Maarten Joost IJzerman, David Lorente, Emma Hall, Carmel Jo Pezaro, J.S. de Bono, Niven Mehra, Aurelius Omlin, Joaquin Mateo, Miguel Miranda
Publikováno v:
European Journal of Cancer. 51:S504
Autor:
Aurelius Omlin, Nikhil Babu Oommen, David Olmos, Andrea Zivi, Joanne Hunt, Alison H.M. Reid, Gerhardt Attard, Diletta Bianchini, Elizabeth Sheridan, Emilda Thompson, Carmel Jo Pezaro, Deborah Mukherji, J. Mezynski, Johann S. de Bono, Ajit Sarvadikar, Amy Mulick Cassidy, Shahneen Sandhu
Publikováno v:
Journal of Clinical Oncology. 30:4553-4553
4553 Background: AA, a potent oral CYP17A1 inhibitor is approved for treatment of mCRPC with a survival advantage of 4.9 months. In clinical practice, response evaluation remains challenging for pts with mCRPC. CTC conversion from CTC ≥ 5 to CTC <
Autor:
Nina Tunariu, Shahneen Sandhu, Johann S. de Bono, Deborah Mukherji, Aurelius Omlin, Diletta Bianchini, Amy Mulick Cassidy, Carmel Jo Pezaro, Gerhardt Attard
Publikováno v:
Journal of Clinical Oncology. 30:e15134-e15134
e15134 Background: Sarcopenia, or skeletal muscle wasting, is an independent prognostic factor in advanced malignancy (Prado Lancet Onc 2008). Decreased muscle and increased fat are recognized side effects of androgen deprivation therapy. AA is a CYP
Autor:
Johann S. de Bono, Amy Mulick Cassidy, Emilda Thompson, Diletta Bianchini, G. Maier, David Olmos, Shahneen Sandhu, Carmel Jo Pezaro, Gerhardt Attard, Aurelius Omlin, Deborah Mukherji
Publikováno v:
Journal of Clinical Oncology. 30:e15136-e15136
e15136 Background: Median overall survival (mOS) in patients (pts) with metastatic prostate cancer progressing despite castrate levels of testosterone (mCRPC) was 13-16 months (m) in the pre-docetaxel era. These data, obtained from clinical trials, w